期刊文献+

阿哌沙班中基因毒性杂质的LC-MS法测定 被引量:7

Determination of the Genotoxic Impurity in Apixaban by LC-MS
原文传递
导出
摘要 建立了液相色谱-质谱法测定阿哌沙班中的基因毒性杂质3-吗啉基-1-[4-(5-氯戊酰胺基)苯基]-5,6-二氢吡啶-2(1H)-酮(2)。采用Waters Xterra RP18色谱柱,以0.01 mol/L乙酸铵缓冲液∶乙腈为流动相,梯度洗脱。质谱采用电喷雾离子源(ESI),正离子模式,选择离子监测(SIM)模式,监测离子为m/z 392.2。2在10~100 ng/ml浓度范围内线性关系良好,平均回收率为101.5%,RSD为1.7%。最低检测限和最低定量限为2.015和5.038 ng/ml。 A LC-MS method was established for the determination of the genotoxic impurity, 3-morpholino-1- [4-(5-chloropentamido) phenyl]-5,6-dihydropyridin-2 (1H)-one (2), in apixaban. A Waters Xterra RP18 column was used, with the mobile phase of 0.01 mol/L ammonium acetate buffer : acetonitrile by gradient elution. The MS detection was carried out by monitoring m/z 392.2 in selective ion monitoring (SIM) mode with positive electrospray ionization. It was linear for 2 in the range of 10 - 100 ng/ml. The average recovery was 101.5%, with RSD of 1.7%. The LLOD and LLOQ were 2.015 and 5.038 ng/ml, respectively.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2015年第9期1004-1007,共4页 Chinese Journal of Pharmaceuticals
关键词 阿哌沙班 基因毒性杂质 3-吗啉基-1-[4-(5-氯戊酰胺基)苯基]-5 6-二氢吡啶-2(1H)-酮 液相色谱-质谱 测定 apixaban genotoxic impurity 3-morpholino-1- [4- (5-chloropentamido) phenyl] -5,6-dihydropyridin- 2 (1/4)-one LC-MS determination
  • 相关文献

参考文献6

  • 1王磊,钟静芬,时惠麟.口服Xa因子直接抑制剂阿哌沙班的临床研究进展[J].上海医药,2012,33(17):17-20. 被引量:26
  • 2Jiang JA, Ji YF. Alternate synthesis of apixaban (BMS-562247), an inhibitor of blood coagulation factor Xa [J]. Synthetic Commun, 2013, 43 (1): 72-79. 被引量:1
  • 3Miiller L, Mauthe RJ, Riley CM, et al. A rationale fordetermining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity [J]. Regul Toxicol Pharmacol, 2006, 44 (3): 198-211. 被引量:1
  • 4European Medicines Agency. CHMP/QMP/251344/2006 CPMP/SWP/5199/02, EMEA/ Evaluation of medicines for human use, guideline on the limit of genotoxic impurities IS] 2006. 被引量:1
  • 5European Medicines Agency. EMEA/CHMP/SWP/431994/ 2007. Pre-authorization evaluation of medicines for human use, question&answers on the CHMP guideline on the limits ofgenotoxic impurities ES]. 2008. 被引量:1
  • 6U.S. Department of Health and Human Services Food and Drug Administration. Guidance for industry: genotoxic and carcinogenic impurities in drug substances and products: recommended approaches (draft guideline) [S]. 2008. 被引量:1

二级参考文献18

  • 1Donald JP, Michael JO, Stephanie K, et al. Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin- 1-yl) phenyl)-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine-3- carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa[J]. J Med Chem, 2007, 50(22): 5339-5356. 被引量:1
  • 2Kylie L, Mark C. New anticoagulants for the prevention of thromboembolism[J]. Curr Phar Des, 2010, 16(31): 3472- 3474. 被引量:1
  • 3Ann KW. New oral anticoagulants: a practical guide for clinicians[J]. J Thromb Thrombolysis, 2010, 29(2): 182-191. 被引量:1
  • 4Donglu Z, Kan H, Nirmala R, et al. Metabolism,pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits[J]. J Thromb Thrombolysis, 2010, 29(1): 70-80. 被引量:1
  • 5Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans[J]. Drug Metab Dispos, 2008, 37(1 ): 74-81. 被引量:1
  • 6John WE, Martin OD, Salim Y, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment[J]. Am Heart J, 2010, 159(3): 348-353. 被引量:1
  • 7Jennifer C, Jack A. Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict[J]. Expert Opin Investig Dru2s. 2008. 17(12: 1937-1945. 被引量:1
  • 8Roser-Jones C, Becker RC. Apixaban: an emerging oral factor Xa inhibitor[J]. J Thromb Thrombolysis, 2010, 29(1): 141- 146. 被引量:1
  • 9Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement[J]. J Thromb Haemost, 2007, 5(12): 2368-2375. 被引量:1
  • 10Michael RL, Gary ER, Alexander G, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial[J]. Lancet, 2010, 375(9717): 807-815. 被引量:1

共引文献25

同被引文献131

引证文献7

二级引证文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部